Acoramidis Linked to Lower Cardiovascular Event Risk in Women With ATTR-CM
In a post hoc analysis of the phase 3 ATTRibute-CM trial, women receiving acoramidis had a lower risk of cardiovascular-related mortality or first cardiovascular-related hospitalization through month 30 than women receiving placebo. The findings were presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026.
Women accounted for 62 of the 632 participants (9.8%) in the trial’s intention-to-treat population. Of those women, 37 received acoramidis and 25 received placebo. The trial randomized participants 2:1 to receive acoramidis or placebo for 30 months. For this sex-stratified analysis, researchers used a Cox proportional hazards model to assess time to cardiovascular-related mortality or first cardiovascular-related hospitalization. They also assessed change from baseline in N-terminal pro-B-type natriuretic peptide (NT-proBNP) using a mixed-effects model with repeated measures after log transformation.
At baseline, women were older than men on average (79 vs 77 years). More women were in New York Heart Association class III (24% vs 16%), while 76% of women and 72% of men were in class II. Median NT-proBNP was lower among women than men (2015 vs 2349 pg/mL).
Among women, the hazard ratio for cardiovascular-related mortality or first cardiovascular-related hospitalization with acoramidis versus placebo was 0.43 (95% CI, 0.18–1.00; P = .0487). Among men, it was 0.64 (95% CI, 0.49–0.84; P = .0014). The researchers reported that the Kaplan–Meier curves separated early in both groups. The treatment-by-sex interaction was not statistically significant (P = .3705).
Acoramidis also attenuated increases in NT-proBNP compared with placebo in both women and men. The abstract did not provide numerical estimates for the NT-proBNP changes.
The authors concluded that the results in women were consistent with those in the overall trial population. They cautioned that the small number of women enrolled limits the precision of the estimate and called for adequately powered, sex-informed evidence.
Reference
Davis MK, Stern LK, Cuddy SAM, et al. Acoramidis reduces risk of cardiovascular-related mortality and hospitalization in women with transthyretin amyloid cardiomyopathy. Poster 494 presented at: Heart Failure Society of America Annual Scientific Meeting; October 10, 2026; Phoenix, AZ. https://hfsa.org/hfsa-annual-scientific-meeting-2026?utm